{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:40:01Z","timestamp":1791092401829,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[1999,1]]},"abstract":"<jats:p>\n            <jats:italic>Abstract<\/jats:italic>\n            \u2014Stroke-prone spontaneously hypertensive rats (SHRSP) on 1% NaCl drinking solution and Stroke-Prone Rodent Diet develop severe hypertension and glomerular and vascular lesions characteristic of thrombotic microangiopathy seen in malignant nephrosclerosis. We recently reported that spironolactone, a mineralocorticoid receptor antagonist, markedly reduced proteinuria and malignant nephrosclerotic lesions in these animals. This observation, together with our previous findings that angiotensin-converting enzyme inhibitors prevent the development of vascular damage, suggests that mineralocorticoids, as part of the renin-angiotensin-aldosterone system, play a pathophysiological role in this model. In the present study, we examined whether chronic (2-week) infusion of aldosterone can reverse the renal vascular protective effects of captopril in SHRSP. SHRSP received vehicle (n=8); captopril alone (50 mg \u00b7 kg\n            <jats:sup>\u22121<\/jats:sup>\n            \u00b7 d\n            <jats:sup>\u22121<\/jats:sup>\n            , orally) (n=10); aldosterone infusion alone (40 \u03bcg \u00b7 kg\n            <jats:sup>\u22121<\/jats:sup>\n            \u00b7 d\n            <jats:sup>\u22121<\/jats:sup>\n            , SC) (n=7); or captopril and aldosterone at 20 (n=6) or 40 (n=7) \u03bcg \u00b7 kg\n            <jats:sup>\u22121<\/jats:sup>\n            \u00b7 d\n            <jats:sup>\u22121<\/jats:sup>\n            . Systolic blood pressure was markedly elevated in all groups. Vehicle- and aldosterone-infused SHRSP developed severe proteinuria and comparable degrees of renal injury (21\u00b13% and 29\u00b13%, respectively) manifested as thrombotic and proliferative lesions in the arterioles and glomeruli. Captopril treatment reduced plasma aldosterone levels concomitant with marked reductions in proteinuria and the absence of histologic lesions of malignant nephrosclerosis. Aldosterone substitution at 20 or 40 \u03bcg \u00b7 kg\n            <jats:sup>\u22121<\/jats:sup>\n            \u00b7 d\n            <jats:sup>\u22121<\/jats:sup>\n            in captopril-treated SHRSP resulted in the development of severe renal lesions (16\u00b13% and 21\u00b12%, respectively) and proteinuria comparable with that observed in SHRSP given either aldosterone or vehicle alone. These findings support a major role for aldosterone in the development of malignant nephrosclerosis in saline-drinking SHRSP, independent of the effects of blood pressure.\n          <\/jats:p>","DOI":"10.1161\/01.hyp.33.1.232","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:53:46Z","timestamp":1339462426000},"page":"232-237","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":240,"title":["Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats"],"prefix":"10.1161","volume":"33","author":[{"given":"Ricardo","family":"Rocha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen N.","family":"Chander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Charles T.","family":"Stier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","unstructured":"Laragh JH Sealey JE. The renin-angiotensin-aldosterone system in hypertensive disorders: A key to two forms of arteriolar contriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis. In Laragh JH Brenner BM (eds). Hypertension: Pathophysiology Diagnosis and Management. New York Raven Press Publishers 1990 pp 1329\u20131348."},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.36.2.234807"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111349"},{"key":"e_1_3_2_4_2","first-page":"1","volume":"52","year":"1968","unstructured":"Hill GS, Heptinstall RH. Steroid-induced hypertension in the rat. Am J Pathol. 1968;52:1\u201339.","journal-title":"Am J Pathol"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-7061(94)00179-F"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Schiffrin EL Thome FS Genest J. Vascular angiotensin II receptors in renal and DOCA-salt hypertensive rats. Hypertension. 1983;5(supp V):V16\u2013V21.","DOI":"10.1161\/01.HYP.5.6_Pt_3.V16"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/4.8.680"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.13.2.115"},{"key":"e_1_3_2_9_2","unstructured":"Stier CT Jr Adler LA Levine S Chander PN. Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens. 1993;11(supp 3):S37\u2013S42."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/6.11.951"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199301000-00006"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199001000-00012"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ph.50.030188.002205"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.31.1.451"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1986.00360230061010"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.28.9.1821"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118867"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.4.3.374"},{"key":"e_1_3_2_19_2","first-page":"893","volume":"120","year":"1992","unstructured":"Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120:893\u2013901.","journal-title":"J Lab Clin Med"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/atvb.17.6.1152"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Diz DI Chappell MC Bosch SM Westwood B Ganten D Ferrario CM Dean RH. Spironolactone increases survival in mREN2(27) transgenic rats with malignant hypertension. Am J Hypertens. 1998;11(4 part 2):34A.","DOI":"10.1016\/S0895-7061(97)90821-9"},{"key":"e_1_3_2_22_2","first-page":"E657","volume":"32","year":"1995","unstructured":"Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol. 1995;32:E657\u2013E662.","journal-title":"Am J Physiol"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(97)00097-7"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.26.6.971"},{"key":"e_1_3_2_25_2","first-page":"E883","volume":"271","year":"1996","unstructured":"Young MJ, Funder JW. The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol. 1996;271:E883\u2013E888.","journal-title":"Am J Physiol"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.26.1.101"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.0910457"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Pitt B. ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). Eur Heart J. 1995;16(suppl N):107\u2013110.","DOI":"10.1093\/eurheartj\/16.suppl_N.107"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.29.1.45"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.HYP.33.1.232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T17:38:55Z","timestamp":1715535535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.HYP.33.1.232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,1]]}},"alternative-id":["10.1161\/01.HYP.33.1.232"],"URL":"https:\/\/doi.org\/10.1161\/01.hyp.33.1.232","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,1]]},"assertion":[{"value":"1998-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-10-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}